Kiniksa Pharmaceuticals . Class A Stock Earnings Reports

Kiniksa reported strong commercial momentum in Q3 2025 driven by ARCALYST (IL-1 alpha and beta inhibition) with quarterly revenue of $180.9M (up 61% YoY). Management raised full-year ARCALYST net sales guidance to $670M–$675M (previously $625M–$640M), citing record new prescribers (+350 in Q3 to >3,825 total) and longer treatment duration (average total duration ~32 months). Penetration remains early (about 15% of the multi‑recurrence population), and ~20% of prescriptions are for first recurrence patients, highlighting upside. Kiniksa’s collaboration profit for ARCALYST grew 118% YoY to $126.6M; operating expenses rose 29% YoY to $156.8M. The company reported net income of $18.4M in the quarter (versus a loss a year ago) and cash of ~$352.1M, and expects to remain cash-flow positive on an annual basis. Pipeline: KPL-387 (fully owned monoclonal IL-1 receptor antagonist) received FDA Orphan Drug Designation for pericarditis; Phase II dose‑focusing data are expected in H2 2026, with 300 mg monthly identified as the anchor dose. Management emphasizes ARCALYST’s role as a steroid-sparing standard of care per recent U.S. guidance and highlights broad patient/physician interest in a monthly self‑injectable option (KPL-387) to expand the market. Key risks: standard forward-looking disclaimers and reliance on continued commercial execution, payer approvals, and positive clinical readouts for KPL-387.